EAST END GROUP, LLC

Lobbying for SEQIRUS · Develop and manufacture influenza vaccines.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · House · Senate · $45,000.00 income · posted Oct 17, 2025

Lobbying activity 1

Health Issues

Legislatives issues related to pandemic preparedness and response. Drug pricing reform. Reauthorization of the Pandemic and All-Hazards Preparedness Act. Funding for pandemic influenza in the LHHS Appropriations bill. Regulatory issues related to development and procurement of pandemic influenza vaccines.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.